Ensysce Biosciences, Inc. · NASDAQ:ENSC
Ensysce Biosciences — Investor Presentation (August 2026)
26 slides from Ensysce Biosciences's investor presentation, Aug 6, 2026
Slide 1: The birth of Ischysogenics
Cy Biopharma The birth of Ischysogenics A new class for pain July 2026 analgesic /sneljezik adj. Acting to relieve pain ischysogenic /iskisso.djenik adj. Acting to increase strength, resilience, or restorative capacity in a biological or psychological system 2. Pertaining to interventions that enhan
Slide 2: Disclaimers
Cy Biopharma Disclaimers ‘This prosetaton is boing fried sol forthe purpose of coniering 2 potent tnsacton the "NrasestorliniingGy Bloharn, ne th “Company and Eneyaee lossanes ne Ere” ata hogan) By tenga prea heat evades sh ate los such infomation tary prea, a that he ein shal au sich nation ay {ein
Slide 3: The Problem
The Problem CRPS — Refractory severe chronic pain - No currently approved therapy, rare disease eligible for orphan designation ° The treatment options for CRPS can include interventional procedures ranging from $30,000 to $150,000" - Estimated that ~200,000°* people are living with CRPS in the US a
Slide 4: Anatomical Problem
Cy Biopharma July 2026 Anatomical Problem CRPS: Maladaptive neuroplasticity Structural and functional brain changes include: CRPS is characterized by a combination of central sensitization, impaired descending modulation, and peripheral neuro-immune and sympathetic mechanisms, which vary by patient
Slide 5: CY200 - Neural reset for CRPS!
CY200 - Neural reset for CRPS! US FDA Orphan Drug Designation granted for active moiety for the treatment of CRPS Botanically extracted psilocybin capsules and proprietary psilocin-dominant formulation? Ongoing active moiety PoC has generated initial medical plausibility sufficient for Orphan Design
Slide 6: CRPS Patent Strategy
Cy Biopharma July 2026 CRPS Patent Strategy Assume that Orphan Drug Exclusivity is only our first line of defence, not our moat. The goal is to create 10-20 overlapping patent families that expire between approximately 2047 and 2052, making it extremely difficult for a competitor using generic psilo
Slide 7: Psilocybin prodrug for Psilocin
Cy Biopharma uly 2026 Psilocybin prodrug for Psilocin CY200 (Psilocybin) Ho 7 ‘y= oo noc om) \ N H Psilocybin © Prodrug © Published data in multiple clinical indications © _ Established development pathway (ODD) 1. SHTZA serotonin receptor agonist 2, Peilocin has been unstable; potentially novel CY2
Slide 8: Therapy overview
Cy Biopharma Cy Biopharma therapy overview 44449 09 Mechanisms of Action hypothesized for psychedelics in chronic pain’ Botanical extract may confer greater size & durability of the effect? Two oral formulations CY200 - Oral capsule CY201 - Oral liquid * potential composition of matter & distributio
Slide 9: Psilocin: Mechanisms of Action in chronic pain
Cy Biopharma uly 2026 48 Psilocin: Mechanisms of Action in chronic pain serotonergic modulation of neural networks’, inflammation & neuroimmune axis? Neural reset: Anti-inflammatory Role: Preclinical studies: Psilocybin prodrug converted to active moiety psilocin Psilocybin may reduce neuroinflammat
Slide 10: CY200/201 increase neuro-restorative biomarkers
Cy Biopharma July 2026 CY200/201 increase neuro-restorative biomarkers Synaptic Proteins! Mechanisms of Action A apa Ps ri 5 PME ME GAP43 (Growth-Associated Protein 43)" _Synaptophysin* PSiL Function: Function: * Apresynaptic protein critical for axonal * Major presynaptic vesicle protein : growth,
Slide 11: From 5-HT pre-existing clinical data in pain...
Cy Biopharma: Joly 2028 From 5-HT pre-existing clinical data in pain... 1964 1969 1973 2 1977 Kast and Collins report LSD has superior analgesic action to pethidine and dihydromorphine. Providing analgesia for at least 7 hours post dose in 74.4% and 19 hours in 48.9% in patients with severe pain rel
Slide 12: ... to present day clinical PoCs
Cy Biopharma uly 2026 ... to present day clinical PoCs 2006 2015 2018 2023 2024 3 2024 Sewell et al. interview 53 patients that were self- medicating their cluster headaches with LSD andior psilocybin. Episodes of cluster headache ceased (n=7/8 LSD users, n=25/48 psilocybin users) or the duration of
Slide 13: New Clinical Data
New Clinical Data a Independent academic & Cy Biopharma sponsored generic psilocybin treatment in CRPS (Not CY200/201) to generate medical plausibility data, designated by the FDA as an orphan drug 2023 (Lyes etal.) (05g mushrooms doses. NYU Langone Health, Treatment resistant CRPS. Pain Johns Hopki
Slide 14: Estimated Initial Market Opportunity: $1.69B+ (CY200 in CRPS)
Cy Biopharma Estimated Initial Market Opportunity: $1.69B+ (CY200 in CRPS)! CY200 Modeled launch uptake and peak sales (Mid case) 18 16 B & Peak sales (USD Billions) ° SS © ® © g 02 2028 2029 2030 2031 2032 2083 2034 Year 41, Management estimates based on internal analysis and review of published li
Slide 15: Proprietary novel 5-HT agonist library
Cy Biopharma July 2026 Figure 1: Agonist Concentration response curve of compounds Proprietary novel 5-HT agonist library against HT1A receptor! ; =) evsoat =) eaiom t=) yao N t a ie ¥ so. B s00- ext generation ic Fe ic ee ea ae NCEs planned CY30X/40X i* i: i: * 24soe one * sezteuns * 2anaeane ° Lop
Slide 16: Pipeline and anticipated milestones
Pipeline and anticipated m Compound Indication Discovery Preclinical Phase1a Phase 1b Phase 2 Phase 3 Fosse fegulatony 3 Complex Regional cy200 Pain Syndrome cy201 Not disclosed (orphan) GD 0127 2030 CY40X Open Funding from National Institute on Drug Abuse (NIDA)
Slide 17: Anticipated Development Plan - CY200 NDA Submission by end 2028
Cy Biopharma July 2026 Cy Biopharma Anticipated Development Plan- Potentially Achieving CY200 NDA Submission by end 2028 2026 (2027 2028 Qi a2 Q3 a4 Qi Q2 a3 a4 Qi Q2 Q3 04 cY200 va CY200 or 201 CRPS Pha: Pivotal Regulatory @ muita scientific Meeting @ Emaconsuttation @ Emaconsuttation @ FDAtypecmes
Slide 18: Randomised, double-blind, controlled Phase 2 Trial
Cy Biopharma July 2026 19 A randomised, double-blind, controlled Phase 2Trial assessing efficacy, safety and tolerability of CY200 for symptom alleviation in participants with Complex Regional Pain Syndrome (CRPS) Type 1 Phase 2 Double-blind study period Day 0 Day 21 Days 42- 105 Screening period >
Slide 19: Randomised, double-blind, controlled Phase 3 Trial
Cy Biopharma July 2026 A randomised, double-blind, controlled’ Phase 3Trial assessing efficacy, safety and tolerability of CY200 for symptom alleviation in SERS eel : z participants with Complex Regional Pain Syndrome (CRPS) Type 1 Fase 3 responders whose pain Supine oti Phase 3: H1 2027 Double-blin
Slide 20: Team
Cy Biopharma July 2026 Team Prof. Richard Langford Roger Sawhney MD James Morrison LLB BCL Eric Bouilloux MSc FRCA, FFPMRCA, FRSM Linkedin LinkedIn LinkedIn Linkedin CFO/CBO, former Director at KKR CEO, Founder and patient advocate COO, proven clinical, regulatory and CMO, Past President of British
Slide 21: Joining forces with...
Cy Biopharma July 2026 2 Joining forces with... D. Lynn Kirkpatrick, PhD Dave Humphrey Geoff Birkett Linda Pestano, PhD : m Schmidt, PhD Chief Executive Officer Chief Financial Officer Chief Commercial Officer Chief Development Officer Chief Medical Officer LinkedIn LinkedIn Linkedin Linkedin Linked
Slide 22: Appendix
Cy Biopharma Appendix
Slide 23: Appendix: Analogues
Cy Biopharma July 2026 Appendix: Analogues? Product Indication Disease Unmet Population Generic product Scheduled Administration FY2025 severity need size competition drug sales Cy Biopharma Orphan Pain High High Rare Disease Medium Yes Oral, dose finding (C¥200), Condition opportunity : : ; : : Nas
Slide 24: Distribution thesis
CY200/201 distribution thesis CY200/201 Patients Will Likely Not Defect to Psychedelic Retreats Evidence-based behaviour analogue: Epidiolex, Spravato, and regulated vs unregulated access Zon DEA Prlin Org Fst Sheet ~ piebin cise 2 Tuoprevas 204 is nd sey condensin pychede at stings PMC) — Nonlahis
Slide 25: ENSC: Advancing Safer Prescription Medicines
Biopharma July 2026 ENSC: Advancing Safer Prescription Medicines © — Government funding from National Institute on Drug MPAR®: Chemical Safety Switch ‘Abuse |&: FDA Breakthrough Therapy, designation Mult-Pill Abuse Resistance: Combination of Product for Overdose Protection © Mission to develop diffe
Slide 26: PF614-MPAR Pain Relief with Overdose Protection
July 2026 PF614-MPAR Pain Relief with Overdose Protection Phase 1 Clinical Study Demonstrating Overdose Protection PF614 alone no MPAR? overdose protection PF614-MPAR 25 mg with MPAR? overdose protection i 0 PF614 alone no overdose protection E 100 E 100 = a Pes © § = S 80 3 80 E e p<0100333 8 3 60
Ensysce Biosciences — Investor Presentation (August 2026) on 6ix